{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:43:19Z","timestamp":1788403399340,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health","award":["Ricerca Corrente 2023 and 2024"],"award-info":[{"award-number":["Ricerca Corrente 2023 and 2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50665-1","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:44:05Z","timestamp":1777794245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mutational profile of atypical fibroxanthoma and pleomorphic dermal sarcoma further expands the spectrum of genomic alterations in rare cutaneous neoplasms"],"prefix":"10.1038","volume":"16","author":[{"given":"Elisabetta","family":"Caprini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Luca","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Scarponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Marani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Scala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Albanesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siavash","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"key":"50665_CR1","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.det.2019.02.001","volume":"37","author":"T Soleymani","year":"2019","unstructured":"Soleymani, T., Aasi, S. Z., Novoa, R. & Hollmig, S. T. Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management. Dermatol. Clin. 37, 253\u2013259 (2019).","journal-title":"Dermatol. Clin."},{"key":"50665_CR2","first-page":"235","volume":"20","author":"D Helbig","year":"2022","unstructured":"Helbig, D. et al. S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). JDDG - J. Ger. Soc. Dermatology. 20, 235\u2013243 (2022).","journal-title":"JDDG - J. Ger. Soc. Dermatology"},{"key":"50665_CR3","first-page":"630","volume":"15","author":"J Kohlmeyer","year":"2017","unstructured":"Kohlmeyer, J., Steimle-Grauer, S. A. & Hein, R. Cutaneous sarcomas. JDDG J. der Dtsch. Dermatologischen Gesellschaft. 15, 630\u2013648 (2017).","journal-title":"JDDG J. der Dtsch. Dermatologischen Gesellschaft"},{"key":"50665_CR4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/modpathol.2013.168","volume":"27","author":"KG Griewank","year":"2014","unstructured":"Griewank, K. G. et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod. Pathol. 27, 502\u2013508 (2014).","journal-title":"Mod. Pathol."},{"key":"50665_CR5","unstructured":"KOCH, M. et al. Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy. Anticancer Res. 35, 5717 LP \u2013 5735 (2015)."},{"key":"50665_CR6","first-page":"392","volume":"112","author":"N Iglesias-Pena","year":"2021","unstructured":"Iglesias-Pena, N., Mart\u00ednez-Campayo, N. & L\u00f3pez-Solache, L. Relation Between Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Histopathologic Features and Review of the Literature. Actas Dermo-Sifiliogr\u00e1ficas (English Ed. 112, 392\u2013405 (2021).","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Ed."},{"key":"50665_CR7","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/PAS.0b013e31825359e1","volume":"36","author":"K Miller","year":"2012","unstructured":"Miller, K., Goodlad, J. R. & Brenn, T. Pleomorphic dermal sarcoma: Adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am. J. Surg. Pathol. 36, 1317\u20131326 (2012).","journal-title":"Am. J. Surg. Pathol."},{"key":"50665_CR8","doi-asserted-by":"crossref","first-page":"T572","DOI":"10.1016\/j.ad.2023.06.010","volume":"114","author":"M Pons Benavent","year":"2023","unstructured":"Pons Benavent, M. et al. [Translated article] Lymphovascular Invasion and High Mitotic Count Are Associated With Increased Risk of Recurrence in Pleomorphic Dermal Sarcoma. Actas Dermosifiliogr. 114, T572\u2013T579 (2023).","journal-title":"Actas Dermosifiliogr"},{"key":"50665_CR9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/cup.12603","volume":"43","author":"JC Tard\u00edo","year":"2016","unstructured":"Tard\u00edo, J. C. et al. Pleomorphic dermal sarcoma: A more aggressive neoplasm than previously estimated. J. Cutan. Pathol. 43, 101\u2013112 (2016).","journal-title":"J. Cutan. Pathol."},{"key":"50665_CR10","first-page":"693","volume":"33","author":"HL Anderson","year":"2007","unstructured":"Anderson, H. L. & Joseph, A. K. A pilot feasibility study of a rare skin tumor database. Dermatol. Surg. 33, 693\u2013696 (2007).","journal-title":"Dermatol. Surg."},{"key":"50665_CR11","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/ajd.13102","volume":"61","author":"N Iglesias-Pena","year":"2020","unstructured":"Iglesias-Pena, N. et al. Incidence rate and clinicopathological features of 62 atypical fibroxanthomas in a North-Western Spanish population. Australas J. Dermatol. 61, e22\u2013e27 (2020).","journal-title":"Australas J. Dermatol."},{"key":"50665_CR12","unstructured":"Fruergaard, O., \u00d8rholt, M., Vester-Glowinski, P. V. & Jensen, D. H. The incidence of atypical fibroxanthoma and pleomorphic dermal sarcoma in Denmark from 2002 to 2022. Surg Oncol 57, (2024)."},{"key":"50665_CR13","first-page":"11","volume":"145","author":"AP Dei Tos","year":"1994","unstructured":"Dei Tos, A. P. et al. Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am. J. Pathol. 145, 11 (1994).","journal-title":"Am. J. Pathol."},{"key":"50665_CR14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/hupa.2001.28953","volume":"32","author":"A Sakamoto","year":"2001","unstructured":"Sakamoto, A. et al. K-, and N-ras gene mutation in atypical fibroxanthoma and malignant fibrous histiocytoma. Hum. Pathol. 32, 1225\u20131231 (2001).","journal-title":"Hum. Pathol."},{"key":"50665_CR15","doi-asserted-by":"crossref","first-page":"21763","DOI":"10.18632\/oncotarget.7845","volume":"7","author":"D Helbig","year":"2016","unstructured":"Helbig, D. et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 7, 21763\u201321774 (2016).","journal-title":"Oncotarget"},{"key":"50665_CR16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/modpathol.2017.146","volume":"31","author":"KG Griewank","year":"2018","unstructured":"Griewank, K. G. et al. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1\/2 and FAT1 mutations and similar DNA copy number alteration profiles. Mod. Pathol. 31, 418\u2013428 (2018).","journal-title":"Mod. Pathol."},{"key":"50665_CR17","doi-asserted-by":"crossref","first-page":"109457","DOI":"10.18632\/oncotarget.22691","volume":"8","author":"D Helbig","year":"2017","unstructured":"Helbig, D. et al. Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 8, 109457\u2013109467 (2017).","journal-title":"Oncotarget"},{"key":"50665_CR18","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-20-1899","volume":"26","author":"S Klein","year":"2020","unstructured":"Klein, S. et al. Integrative analysis of pleomorphic dermal sarcomas reveals fibroblastic differentiation and susceptibility to immunotherapy. Clin. Cancer Res. 26, 5638\u20135645 (2020).","journal-title":"Clin. Cancer Res."},{"key":"50665_CR19","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/genes12070974","volume":"12","author":"M Ak","year":"2021","unstructured":"Ak, M. et al. Clinicopathological and genomic profiles of atypical fibroxanthoma and pleomorphic dermal sarcoma identify overlapping signatures with a high mutational burden. Genes (Basel). 12, 974 (2021).","journal-title":"Genes (Basel)"},{"key":"50665_CR20","doi-asserted-by":"publisher","unstructured":"Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 1\u201316. https:\/\/doi.org\/10.1200\/PO.17.00011\/ (2017).","DOI":"10.1200\/PO.17.00011\/"},{"key":"50665_CR21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.humpath.2020.06.003","volume":"102","author":"TI Miller","year":"2020","unstructured":"Miller, T. I. et al. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations. Hum. Pathol. 102, 60\u201369 (2020).","journal-title":"Hum. Pathol."},{"key":"50665_CR22","doi-asserted-by":"crossref","first-page":"e0188272","DOI":"10.1371\/journal.pone.0188272","volume":"12","author":"K Lai","year":"2017","unstructured":"Lai, K. et al. Genomic analysis of atypical fibroxanthoma. PLoS One. 12, e0188272 (2017).","journal-title":"PLoS One"},{"key":"50665_CR23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/PAS.0000000000000389","volume":"39","author":"NP Agaram","year":"2015","unstructured":"Agaram, N. P. et al. Dichotomy of Genetic Abnormalities in PEComas with Therapeutic Implications. Am. J. Surg. Pathol. 39, 813 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"50665_CR24","first-page":"1022","volume":"54","author":"RH Lekanne Deprez","year":"1994","unstructured":"Lekanne Deprez, R. H. et al. Frequent NF2 Gene Transcript Mutations in Sporadic Meningiomas and Vestibular Schwannomas. Am. J. Hum. Genet. 54, 1022 (1994).","journal-title":"Am. J. Hum. Genet."},{"key":"50665_CR25","doi-asserted-by":"crossref","unstructured":"Xu, D., Yin, S. & Shu, Y. NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity. npj Precis. Oncol. 8, 1\u201317 (2024). (2024).","DOI":"10.1038\/s41698-024-00627-5"},{"key":"50665_CR26","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel, L. et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol. Oncol. 14, 1207\u20131223 (2020).","journal-title":"Mol. Oncol."},{"key":"50665_CR27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.devcel.2010.10.008","volume":"19","author":"AB Gladden","year":"2010","unstructured":"Gladden, A. B., Hebert, A. M., Schneeberger, E. E. & McClatchey, A. I. The NF2 Tumor Suppressor, Merlin, Regulates Epidermal Development through the Establishment of a Junctional Polarity Complex. Dev. Cell. 19, 727\u2013739 (2010).","journal-title":"Dev. Cell."},{"key":"50665_CR28","doi-asserted-by":"crossref","unstructured":"Liu, Z. L., Chen, H. H., Zheng, L. L., Sun, L. P. & Shi, L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct. Target. Ther. 8, 1\u201339 (2023). (2023).","DOI":"10.1038\/s41392-023-01460-1"},{"key":"50665_CR29","doi-asserted-by":"crossref","unstructured":"Nacev, B. A. et al. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nat. Commun. 13, 1\u201315 (2022). (2022).","DOI":"10.1038\/s41467-022-30453-x"},{"key":"50665_CR30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1101\/gad.1067403","volume":"17","author":"EJ Brown","year":"2003","unstructured":"Brown, E. J. & Baltimore, D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 17, 615\u2013628 (2003).","journal-title":"Genes Dev."},{"key":"50665_CR31","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/0008-5472.CAN-04-1289","volume":"64","author":"H Wang","year":"2004","unstructured":"Wang, H., Wang, H., Powell, S. N., Iliakis, G. & Wang, Y. ATR Affecting Cell Radiosensitivity Is Dependent on Homologous Recombination Repair but Independent of Nonhomologous End Joining. Cancer Res. 64, 7139\u20137143 (2004).","journal-title":"Cancer Res."},{"key":"50665_CR32","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1126\/science.1083430","volume":"300","author":"L Zou","year":"2003","unstructured":"Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Sci. (80-). 300, 1542\u20131548 (2003).","journal-title":"Sci. (80-)"},{"key":"50665_CR33","doi-asserted-by":"crossref","first-page":"39058","DOI":"10.1074\/jbc.M506921200","volume":"280","author":"K Yang","year":"2005","unstructured":"Yang, K. et al. Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation. J. Biol. Chem. 280, 39058\u201339066 (2005).","journal-title":"J. Biol. Chem."},{"key":"50665_CR34","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1038\/sj.emboj.7601833","volume":"26","author":"O Ichikawa","year":"2007","unstructured":"Ichikawa, O. et al. Structural basis of the collagen-binding mode of discoidin domain receptor 2. EMBO J. 26, 4168\u20134176 (2007).","journal-title":"EMBO J."},{"key":"50665_CR35","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.cellsig.2006.02.012","volume":"18","author":"WF Vogel","year":"2006","unstructured":"Vogel, W. F., Abdulhussein, R. & Ford, C. E. Sensing extracellular matrix: An update on discoidin domain receptor function. Cell. Signal. 18, 1108\u20131116 (2006).","journal-title":"Cell. Signal."},{"key":"50665_CR36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/gutjnl-2011-300810","volume":"61","author":"I Badiola","year":"2012","unstructured":"Badiola, I., Olaso, E., Crende, O., Friedman, S. L. & Vidal-Vanaclocha, F. Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut 61, 1465\u20131472 (2012).","journal-title":"Gut"},{"key":"50665_CR37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12307-011-0074-7","volume":"4","author":"N Beauchemin","year":"2011","unstructured":"Beauchemin, N. The colorectal tumor microenvironment: The next decade. Cancer Microenviron. 4, 181\u2013185 (2011).","journal-title":"Cancer Microenviron"},{"key":"50665_CR38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb2743","volume":"15","author":"K Zhang","year":"2013","unstructured":"Zhang, K. et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat. Cell. Biol. 15, 677\u2013687 (2013).","journal-title":"Nat. Cell. Biol."},{"key":"50665_CR39","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/path.4415","volume":"234","author":"T Ren","year":"2014","unstructured":"Ren, T. et al. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial\u2013mesenchymal transition programme under hypoxia. J. Pathol. 234, 526\u2013537 (2014).","journal-title":"J. Pathol."},{"key":"50665_CR40","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","volume":"65","author":"F Van Roy","year":"2008","unstructured":"Van Roy, F. & Berx, G. The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 65, 3756\u20133788 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"50665_CR41","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1038\/sj.onc.1202790","volume":"18","author":"G Handschuh","year":"1999","unstructured":"Handschuh, G. et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 18, 4301\u20134312 (1999).","journal-title":"Oncogene"},{"key":"50665_CR42","unstructured":"Al-Ahmadie, H. A. et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat. Genet. 48, 356\u2013358 (2016). (2016)."},{"key":"50665_CR43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","volume":"271","author":"DJ Rawlings","year":"1996","unstructured":"Rawlings, D. J. et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Sci. (80-). 271, 822\u2013825 (1996).","journal-title":"Sci. (80-)"},{"key":"50665_CR44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/gcc.22091","volume":"52","author":"C Eifert","year":"2013","unstructured":"Eifert, C. et al. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis. Genes Chromosom Cancer. 52, 961\u2013975 (2013).","journal-title":"Genes Chromosom Cancer"},{"key":"50665_CR45","first-page":"4368","volume":"3533 35","author":"E Grassilli","year":"2016","unstructured":"Grassilli, E. et al. A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. Oncogene 2016. 3533 35, 4368\u20134378 (2016).","journal-title":"Oncogene 2016"},{"key":"50665_CR46","first-page":"1","volume":"38","author":"F Giordano","year":"2019","unstructured":"Giordano, F. et al. P65BTK is a novel potential actionable target in KRAS-mutated\/EGFR-wild type lung adenocarcinoma. J. Exp. Clin. Cancer Res. 38, 1\u201316 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"50665_CR47","first-page":"3003","volume":"8","author":"JD Wang","year":"2016","unstructured":"Wang, J. D., Chen, X. Y., Ji, K. W. & Tao, F. Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth. Am. J. Transl Res. 8, 3003 (2016).","journal-title":"Am. J. Transl Res."},{"key":"50665_CR48","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1080\/15384047.2015.1078023","volume":"16","author":"L Kokabee","year":"2015","unstructured":"Kokabee, L. et al. Bruton\u2019s tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol. Ther. 16, 1604\u20131615 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"50665_CR49","first-page":"1","volume":"36","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. J. Exp. Clin. Cancer Res. 36, 1\u201313 (2017).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"50665_CR50","doi-asserted-by":"crossref","first-page":"13255","DOI":"10.18632\/oncotarget.3658","volume":"6","author":"MA Zucha","year":"2015","unstructured":"Zucha, M. A. et al. Bruton\u2019s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget 6, 13255\u201313268 (2015).","journal-title":"Oncotarget"},{"key":"50665_CR51","doi-asserted-by":"crossref","unstructured":"Leichtle, F. et al. Influence of Bruton\u2019s Tyrosine Kinase (BTK) on Epithelial\u2013Mesenchymal Transition (EMT) Processes and Cancer Stem Cell (CSC) Enrichment in Head and Neck Squamous Cell Carcinoma (HNSCC). Int. J. Mol. Sci. Vol. 24, Page 13133 24, 13133 (2023). (2023).","DOI":"10.3390\/ijms241713133"},{"key":"50665_CR52","first-page":"1472","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 2014 2012. 20, 1472\u20131478 (2014).","journal-title":"Nat. Med. 2014 2012"},{"key":"50665_CR53","doi-asserted-by":"crossref","unstructured":"Gao, J. et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal 6, (2013).","DOI":"10.1126\/scisignal.2004088"},{"key":"50665_CR54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov"},{"key":"50665_CR55","doi-asserted-by":"crossref","first-page":"e64016","DOI":"10.2196\/64016","volume":"27","author":"JT Fekete","year":"2025","unstructured":"Fekete, J. T. & Gy\u0151rffy, B. MetaAnalysisOnline.com: Web-Based Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies. J. Med. Internet Res. 27, e64016 (2025).","journal-title":"J. Med. Internet Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50665-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50665-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50665-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:03:10Z","timestamp":1783080190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50665-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50665"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50665-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20438"}}